WINTON GROUP Ltd Decreases Stock Holdings in Ironwood Pharmaceuticals, Inc. $IRWD

WINTON GROUP Ltd decreased its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 65.2% during the second quarter, HoldingsChannel reports. The institutional investor owned 84,156 shares of the biotechnology company’s stock after selling 157,590 shares during the period. WINTON GROUP Ltd’s holdings in Ironwood Pharmaceuticals were worth $354,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in IRWD. LSV Asset Management acquired a new position in Ironwood Pharmaceuticals during the fourth quarter worth $30,000. DGS Capital Management LLC purchased a new position in Ironwood Pharmaceuticals during the fourth quarter valued at $35,000. Simplify Asset Management Inc. acquired a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at about $37,000. Principal Financial Group Inc. acquired a new stake in shares of Ironwood Pharmaceuticals in the first quarter valued at about $40,000. Finally, MQS Management LLC purchased a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth about $42,000.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD stock opened at $4.17 on Thursday. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $1.26 and a fifty-two week high of $5.78. The stock’s fifty day moving average is $4.14 and its two-hundred day moving average is $3.89. The firm has a market capitalization of $689.05 million, a P/E ratio of 5.42 and a beta of 0.20.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The business had revenue of $113.04 million for the quarter, compared to analysts’ expectations of $114.84 million. Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%. On average, equities analysts forecast that Ironwood Pharmaceuticals, Inc. will post 1.1 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Ronald Silver sold 127,890 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total transaction of $578,062.80. Following the transaction, the insider directly owned 313,680 shares in the company, valued at approximately $1,417,833.60. The trade was a 28.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 9.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on IRWD. Zacks Research downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Weiss Ratings cut Ironwood Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, September 4th. Finally, Wall Street Zen lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 5th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Ironwood Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $6.23.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused pharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines for gastrointestinal diseases and other disorders where significant unmet medical needs remain.

Ironwood’s primary marketed product is LINZESS (linaclotide), an oral medication used to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The product was approved by the U.S.